Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Tyrosine Protein Kinase Mer pipeline market research report provides a comprehensive overview on the therapeutics under development for Tyrosine Protein Kinase Mer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tyrosine Protein Kinase Mer and features dormant and discontinued projects.
Key Therapy Areas in the Tyrosine Protein Kinase Mer Pipeline Drugs Market
In the MERTK pipeline drugs market the key therapy areas are Oncology, Central Nervous System, and Ophthalmology. Oncology has the highest number of pipeline products.
Tyrosine Protein Kinase Mer Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key MoA in the Tyrosine Protein Kinase Mer Pipeline Drugs Market
Tyrosine Protein Kinase Mer Inhibitor has the highest number of pipeline products followed by Tyrosine Protein Kinase Mer Antagonist, and Tyrosine Protein Kinase Mer Activator.
Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Tyrosine Protein Kinase Mer Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the MERTK pipeline drugs market are Oral, and Intraocular. Oral has the maximum number of pipeline products.
Tyrosine Protein Kinase Mer Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market
The key molecule types in the Tyrosine Protein Kinase Mer pipeline drugs market are Small Molecule, Monoclonal Antibody, and Gene Therapy.
Tyrosine Protein Kinase Mer Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Tyrosine Protein Kinase Mer Pipeline Drugs Market
The major companies in the MERTK pipeline drugs market are Mirati Therapeutics Inc, Meryx Inc, Celon Pharma SA, Eli Lilly and Co, Dong-A Socio Holdings Co Ltd, Exelixis Inc, F. Hoffmann-La Roche Ltd, Halia Therapeutics Inc, HEC Pharma Co Ltd, Hope Biosciences Inc, Incyte Corp, Inspirna Inc, Pfizer Inc, and Qurient Co Ltd.
Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Tyrosine Protein Kinase Mer Pipeline Drugs Market Overview
Key Therapy Areas | Oncology, Central Nervous System, and Ophthalmology |
Key Mechanisms of action | Tyrosine Protein Kinase Mer Inhibitor, Tyrosine Protein Kinase Mer Antagonist, and Tyrosine Protein Kinase Mer Activator |
Key Routes of Administration | Oral, and Intraocular |
Key Molecule Types | Small Molecule, Monoclonal Antibody, and Gene Therapy |
Major Companies | Mirati Therapeutics Inc, Meryx Inc, Celon Pharma SA, Eli Lilly and Co, Dong-A Socio Holdings Co Ltd, Exelixis Inc, F. Hoffmann-La Roche Ltd, Halia Therapeutics Inc, HEC Pharma Co Ltd, Hope Biosciences Inc, Incyte Corp, Inspirna Inc, Pfizer Inc, and Qurient Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tyrosine Protein Kinase Mer
- The pipeline guide reviews pipeline therapeutics for Tyrosine Protein Kinase Mer by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tyrosine Protein Kinase Mer therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tyrosine Protein Kinase Mer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Tyrosine Protein Kinase Mer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tyrosine Protein Kinase Mer
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Aucentra Therapeutics Pty Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Halia Therapeutics Inc
HEC Pharma Co Ltd
Incyte Corp
Inspirna Inc
Mediolanum farmaceutici SpA
Meryx Inc
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Qurient Co Ltd
Table of Contents
Frequently asked questions
-
What are the key therapy areas in the Tyrosine Protein Kinase Mer pipeline drugs market?
In the Tyrosine Protein Kinase Mer pipeline drugs market the key therapy areas are Oncology, Central Nervous System, and Ophthalmology.
-
What are the key mechanisms of action in the Tyrosine Protein Kinase Mer pipeline drugs market?
In the Tyrosine Protein Kinase Mer pipeline drugs market the key mechanisms of action are Tyrosine Protein Kinase Mer Inhibitor, Tyrosine Protein Kinase Mer Antagonist, and Tyrosine Protein Kinase Mer Activator.
-
What are the key routes of administration in the Tyrosine Protein Kinase Mer pipeline drugs market?
The key routes of administration in the Tyrosine Protein Kinase Mer pipeline drugs market are Oral, and Intraocular.
-
What are the key molecule types in the Tyrosine Protein Kinase Mer pipeline drugs market?
The key molecule types in the Tyrosine Protein Kinase Mer pipeline drugs market are Small Molecule, Monoclonal Antibody, and Gene Therapy.
-
What are the major companies in the Tyrosine Protein Kinase Mer pipeline drugs market?
In the Tyrosine Protein Kinase Mer pipeline drugs market the major companies are Mirati Therapeutics Inc, Meryx Inc, Celon Pharma SA, Eli Lilly and Co, Dong-A Socio Holdings Co Ltd, Exelixis Inc, F. Hoffmann-La Roche Ltd, Halia Therapeutics Inc, HEC Pharma Co Ltd, Hope Biosciences Inc, Incyte Corp, Inspirna Inc, Pfizer Inc, and Qurient Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports

